Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Sustained Release Excipients Industry?

In recent years, the leukotriene modifiers market has witnessed robust growth. The market size is projected to increase from $22.33 billion in 2024 to $23.54 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.4%. Factors that can be attributed to this growth in the historical period can include: increased regulatory approval impact, improved awareness about the leukotriene modifiers’ advantages among healthcare personnel and patients, expiration of several patents for leukotriene modifier drugs facilitating the entry of generic versions, broadening applications for leukotriene modifiers, and rising partnerships between pharmaceutical organizations and healthcare institutions.

The market size of leukotriene modifiers is anticipated to experience robust growth in the upcoming years, expanding to “$29.25 billion by 2029 with a compound annual growth rate (CAGR) of 5.6%.” The predicted growth during the forecasted timeframe can be linked to numerous expansion opportunities in emerging markets, fueled by an enhanced healthcare framework and augmenting disposable incomes trend towards personalized healthcare. The increased use of telemedicine and remote patient monitoring, sustained research and development initiatives focusing on new drug candidates and formulations, and the expected alterations in regulation parameters also contribute to this growth. The forecast period will likely see trending integration of digital health technology like mobile apps, wearable devices, AI, and machine learning algorithms. The exploration of new therapeutic objectives, creation of patient participation solutions and tools, and the implementation of continuous manufacturing methods for improved efficiency in drug production are also anticipated trends.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16109&type=smp

What Forces Are Driving The Growth Of The Sustained Release Excipients Industry?

The sustained-release excipients market is poised to experience growth, thanks to the rising incidence of chronic and acute diseases. Chronic illnesses are medical conditions that last longer – usually three months or more, while acute diseases are typically intense but short-lived, lasting only a few hours to days or weeks. Sustained-release excipients, common in the formulation of pharmaceutical products for both disease types, has benefits like improving patient adherence, maintaining uniform drug levels, minimizing side effects, and bettering disease management, thereby enhancing sales. As per the World Health Organization (WHO) in September 2022, the maximum NCD deaths – 17.9 million annually, were due to cardiovascular diseases, followed by chronic respiratory diseases (4.1 million), diabetes-related complications including kidney disease (2.0 million), and cancer (9.3 million). In August 2022, a report from the American College of Cardiology predicted that all major cardiovascular risk factors in the United States would see an upward trend from 2025 to 2060, with diabetes showing the highest percentage increase of 39.3% to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Also, cardiovascular disease rates for stroke and heart failure are expected to significantly increase (33.8% to 15 million and 33.4% to 13 million respectively), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) also showing a marked increase. Thus, the escalating incidence of chronic and acute diseases is a significant factor driving the sustained-release excipients market’s growth.

The leukotriene modifiers market covered in this report is segmented –

1) By Drug Type: Montelukast, Zafirlukast, Zileuton ER, Zileuton

2) By Form: Tablets, Chewable Tablets, Oral Granules

3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies

Subsegments:

1) By Montelukast: Tablet Formulation, Chewable Tablet Formulation, Oral Granules

2) By Zafirlukast: Tablet Formulation

3) By Zileuton ER: Extended-Release Tablet Formulation

4) By Zileuton: Tablet Formulation, Oral Suspension Formulation

What Upcoming Trends Are Expected To Impact The Sustained Release Excipients Market Globally?

Major firms in the leukotriene modifier market are concentrating their efforts on creating generic formulations like extended-release (ER) tablets. This is in an attempt to broaden their range and meet the increasing need for more efficient and convenient treatments. Extended-release tablets are essentially pharmaceutical formulations of medications that gradually release their active components over a longer period, offering improved dosing schedules and convenience relative to immediate-release formulations. For example, Camber Pharmaceuticals Inc., a pharmaceutical firm based in the US, incorporated Zileuton ER Tablets into its product range in April 2023. These tablets are used for the prevention and prolonged treatment of asthma in both adults and children who are 12 years or older. However, they’re not suitable for reversing bronchospasm during an acute asthma attack, but their usage can be continued during severe asthma flare-ups. Zileuton ER Tablets come in 600 mg dosage and are available in bottles of 120.

Who Are The Primary Players Operating Across The Global Sustained Release Excipients Market?

Major companies operating in the leukotriene modifiers market are Merck And Co., Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Chiesi Farmaceutici S.p.A., Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Starallergens Greer Ltd, Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience, Annett Company Inc.

https://www.thebusinessresearchcompany.com/report/leukotriene-modifiers-global-market-report

Which Region Offers The Most Growth Potential For The Sustained Release Excipients Market Through 2029?

North America was the largest region in the leukotriene modifiers market in 2024. The regions covered in the leukotriene modifiers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16109&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model